Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE Any CCR4 positivity was seen in all CD8+ MF cases, in 83% of CD30+ LPD cases, in 75% of AETCL cases, in 33% of GDTCL cases, and in none of the SPTCL cases. 31355940 2020
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE Lymphomatoid papulosis (LyP) is a benign chronic often relapsing skin condition that belongs to the CD30-positive cutaneous lymphoproliferative disorders. 31494989 2020
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE Unlike CD30+ cutaneous LPD, BIA-ALCL cannot be readily observed over time to study the different steps in progression to ALCL. 31577659 2020
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE These were considered in four main categories: primary cutaneous B cell lymphomas (12 cases), primary cutaneous T cell lymphomas/lymphoproliferations with CD8+/cytotoxic phenotype (12 cases), primary cutaneous CD30-positive lymphoproliferative disorders (15 cases) and primary cutaneous T cell lymphomas/leukaemias with CD4+ phenotype (4 cases). 31781845 2019
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE Non-MF/SS PCLs were primarily of T-cell origin (61%) where CD30+ lymphoproliferative disorders predominated, followed by Epstein-Barr virus-induced lymphomas, and peripheral T-cell lymphomas, not otherwise specified. 28400635 2019
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE Primary cutaneous CD8+ and CD30+ T-cell lymphoproliferative disorders: case reports and clinical implications. 30670369 2019
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE CD30+ lymphoproliferative disorders (LD) represent a spectrum of entities ranging from self-limited proliferations or cutaneous lesions with favorable prognosis, such as lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (ALCL), to more aggressive malignancies such as systemic ALK-positive and ALK-negative ALCL. 31705818 2019
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil. 31640798 2019
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies. 30630983 2019
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE Cutaneous CD30lymphoproliferative disorders constitute many cutaneous T-cell lymphomas and comprise lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (ALCL).Both have an excellent prognosis. 31466587 2019
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 GeneticVariation group BEFREE The most frequent CTCL subtypes, in decreasing order of prevalence, were mycosis fungoides (MF), including its variants (75.7%); CD30+ primary cutaneous lymphoproliferative disorders (7.2%); and Sézary syndrome (SS) (3.1%). 30294921 2019
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE Mycosis Fungoides Associated With Lesions in the Spectrum of Primary Cutaneous CD30+ Lymphoproliferative Disorders: The Same Process or 3 Coexisting Lymphomas? 30946099 2019
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE At present, brentuximab vedotin, an antibody-drug conjugate composed of an anti-cluster of differentiation (CD)-30 antibody covalently linked to monomethyl auristatin E, is approved for the treatment of CD30+ lymphoproliferative disorders [lymphomatoid papulosis (LyP) and primary cutaneous-anaplastic large-cell lymphoma (pc-ALCL)] as well as transformed CD30+ mycosis fungoides (MF). 30430444 2019
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE Low-dose total skin electron beam therapy for refractory cutaneous CD30 positive lymphoproliferative disorders. 31179774 2019
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE TUGSE lesions may mimic malignancy such as squamous cell carcinoma, CD30 positive lymphoproliferative disorder, or infectious diseases such as primary syphilis, tuberculosis, or Epstein-Barr virus mucocutaneous ulcer. 31706333 2019
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE CCR3 was expressed in 73% of cases of CD30+ lymphoproliferative disorders such as lymphomatoid papulosis and anaplastic large cell lymphoma. 31045236 2019
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE Brentuximab vedotin is a very interesting new treatment for advanced tumor MF, Sezary syndrome, and primary cutaneous CD30+ lymphoproliferative disorders. 28400633 2019
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE Prospective, nonblinded survey design utilizing questionnaires including panels of QoL indices obtained from 105 patients with mycosis fungoides, Sezary syndrome, and CD30+ lymphoproliferative disorder. 30074622 2018
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE Whereas none of the patients in our index series exhibited EBV positivity, here we discuss a very unique example of a 14-year-old girl diagnosed with EBV positive CD30 positive lymphoproliferative disorder strongly resembling the cases of intra-oral type C lymphomatoid papulosis. 30292067 2018
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE Another photoresponsive CTCL variant is lymphomatoid papulosis (LP), a CD30+ lymphoproliferative disease characterised by chronically recurring papules. 30325389 2018
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 GeneticVariation group BEFREE Fifteen patients with an established diagnosis of cutaneous lymphoma were prospectively recruited and seen in the university multidisciplinary cutaneous lymphoma program with MF, an MF- variant, CD30-positive lymphoproliferative disorder, or cutaneous B-cell lymphomas and were included in our study. 29318585 2018
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE In order of frequency, diagnoses were: mycosis fungoides (40.5%), peripheral T-cell lymphoma not otherwise specified (22.95%), adult T-cell lymphoma/leukemia (18.9%), CD30+ lymphoproliferative disorders (6.8%), hydroa vacciniforme-like lymphoma (5.4%), extranodal NK/T-cell lymphoma (4.1%) and Sézary syndrome (1.4%). 29166501 2018
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment. 29719017 2018
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE PCH predominantly occurs in CD30-positive lymphoproliferative disorders. 29473196 2018
CUI: C0024314
Disease: Lymphoproliferative Disorders
Lymphoproliferative Disorders
0.100 Biomarker group BEFREE Lymphomatoid papulosis is one of the primary cutaneous CD30+ T-cell lymphoproliferative disorders. 28614957 2018